Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Connect Biopharma Holdings Ltd

NASDAQ: CNTB · Life Sciences · 4 alerts · CIK 1835268

Share price
$0.6430Close, Nov 16
Market cap
$41.5M
Shares outstanding
64.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Connect Biopharma Holdings Ltd filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Connect Biopharma Holdings Q3 2026 Results: Net Loss of $16.1M, Loss Narrows

Connect Biopharma reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to $40.4 million in the prior year, primarily driven by a significant increase in research and development expenses. Total assets decreased from $56.1 million at year-end 2025 to $27.8 million as of September 30, 2026, reflecting the company's continued cash burn for clinical operations.

Key figure
Net loss $16.1M
4:29 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Connect Biopharma Holdings Nasdaq/NYSE Compliance Notice

Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.

Counterparty
Nasdaq
Term
180 days

“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma

“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”

Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
7:05 AM ET 8-K
Clinical Trial Data

Connect Biopharma Holdings Clinical Trial Data

Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.

Earnings call
Sep 30, 2026, 8:00 AM ET
7:07 AM ET 8-K
Clinical Trial Data

Connect Biopharma Holdings Clinical Trial Data

Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations. The study met its key secondary endpoint with a statistically significant improvement in lung function (FEV1) at Day 7, and while the primary endpoint of treatment failure reduction (66%) did not reach statistical significance due to lower-than-projected event rates, the company plans to engage with the FDA for a Phase 3 program.

Earnings call
Sep 15, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.